Multiplex Immunohistochemistry (mIHC)
The multiplex immunohistochemistry (mIHC) platform provides an automated, tissue sparing and cost- effective solution for multiplex analysis of up 23 immune markers on a single FFPE slide. mIHC analysis allows for thorough investigation of in situ immune contexture of tumor and stroma.
The multiplex approach allows for prospective and retrospective monitoring of clinical tissue samples:
Baseline, in response to standard of care treatment, in response to immune treatment and longitudinal biopsies
Primary (early and late stage) and metastatic disease
Predictive biomarkers for treatment stratification
Identification of response vs resistance to treatment
On treatment changes in response to treatment
Methodology:
mIHC utilizes chromogen based immuno-detection and antibody stripping chemistry. mIHC antibody panels have been validated using single staining comparisons to multiplex staining on positive control tissues. Automated staining reduces batch variability and inclusion of positive control tissues in every staining batch assure accuracy. This technique offers deep, rapid and automated immune auditing
emphasizing spatial information. Panels are validated in brain, lung, liver, skin, pancreas, breast, lymph node, head and neck, and bone marrow tissue.
